Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Monday

Key Points

• Avalo Therapeutics (AVTX) is set to announce its Q2 2025 earnings results on August 11th, with expectations of reporting a loss of ($1.43) per share.
• The company's previous earnings report showed a miss, with an EPS of ($1.25) compared to an expected ($1.07).
• Avalo Therapeutics has recently received an upgraded rating from "hold" to "buy" by HC Wainwright, with a price target of $15.00.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Avalo Therapeutics to post earnings of ($1.43) per share for the quarter.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.49). On average, analysts expect Avalo Therapeutics to post $-19 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Avalo Therapeutics Stock Performance

Shares of NASDAQ AVTX traded down $0.09 during trading hours on Thursday, hitting $8.22. 5,921 shares of the company traded hands, compared to its average volume of 99,624. The company's 50 day moving average price is $5.31 and its 200 day moving average price is $5.96. Avalo Therapeutics has a 12 month low of $3.39 and a 12 month high of $16.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised shares of Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 target price on the stock in a research note on Monday, June 2nd. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $30.00.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.